FDA gives Lymphoseek orphan drug status
September 19, 2014 -- The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Navidea Biopharmaceuticals' Lymphoseek radiopharmaceutical agent for use in sentinel lymph node detection in patients with head and neck cancer.
ASTRO: Targeted radiation, chemotherapy less toxic for HNC
September 18, 2014 -- Patients with recurring head and neck cancer (HNC) who have previously received radiation treatment can be treated more quickly, safely, and with fewer side effects with high doses of targeted radiation known as stereotactic body radiation therapy (SBRT), combined with drugs that target cancerous tumors, according to research presented at the American Society of Radiation Oncology (ASTRO) meeting in San Francisco.
ASTRO: Radiation therapy alone effective for advanced esophageal cancer
September 16, 2014 -- Radiation therapy alone is as effective as radiation therapy with chemotherapy in decreasing swallowing complications experienced by advanced esophageal cancer patients, thus allowing patients to forgo chemotherapy, according to research presented at this week's American Society for Radiation Oncology (ASTRO) annual meeting.
ASTRO: Blood test could help tailor esophageal cancer treatment
September 15, 2014 -- A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented at this week's American Society for Radiation Oncology (ASTRO) annual meeting in San Francisco.
Univ. of Minnesota joins Multikine clinical trials
September 10, 2014 -- The University of Minnesota Masonic Cancer Center has becomes the seventh clinical site in the U.S. to join the phase III head and neck cancer (HNC) clinical trial of CEL-SCI's investigational cancer immunotherapy treatment Multikine.
Nationwide HPV vaccination program would save billions, extend lives
September 4, 2014 -- A free, nationwide human papillomavirus (HPV) vaccination program for boys and girls would save billions in medical costs and prevent oropharyngeal cancers, according to the Center for Oral Health. Studies show that noncervical HPV-related diseases cost billions annually, and HPV-related oropharyngeal cancer cases will exceed cervical cancers by 2020.
Blood, saliva tests help predict HPV-linked HNC recurrence
August 26, 2014 -- Blood and saliva tests can accurately predict the recurrence of human papillomavirus (HPV)-linked head and neck cancers (HNC), according to a recent study in JAMA Otolaryngology -- Head & Neck Surgery. Finding HPV DNA in both blood and saliva samples after treatment accurately predicted recurrence 70% of the time.
New hope for patients with hard-to-treat head and neck cancers
August 20, 2014 -- Using a technique that looks for genes that tumor cells need to survive, Seattle researchers have identified a potential new drug target for a class of difficult-to-treat head and neck cancers, according to a new study in Clinical Cancer Research.
Aspirin can help battle head/neck cancer
Aspirin appears to offer significant protection against head and neck (HNC) cancer, according to a study in the British Journal of Cancer. Regular aspirin use was associated with a 22% reduction in HNC and seems to be particularly effective in preventing laryngeal cancer.